Felipe de Lara Janz

Dr. Felipe de Lara Janz

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in Journal of Biomedicine and Biotechnology
Verified
Journal Article
Open access
PDF file
FJFelipe de Lara Janz
Felipe de Lara Janz
ADAdriana de Aguiar Debes
Adriana de Aguiar Debes
RCRita de Cássia Cavaglieri
Rita de Cássia Cavaglieri
SDSérgio Aloísio Duarte
Sérgio Aloísio Duarte
CRCarolina Martinez Romão
Carolina Martinez Romão
Sergio BydlowskiSergio Bydlowski
Sergio Bydlowski
Amniotic fluid (AF) was described as a potential source of mesenchymal stem cells (MSCs) for biomedicine purposes. Therefore, evaluation of alternative cryoprotectants and freezing protocols capable to maintain the viability and stemness of these cells after cooling is still needed. AF stem cells (AFSCs) were tested for different freezing methods and cryoprotectants. Cell viability, gene expression, surface markers, and plasticity were evaluated after thawing. AFSCs expressed undifferentiated genes Oct4 and Nanog; presented typical markers (CD29, CD44, CD90, and CD105) and were able to differentiate into mesenchymal lineages. All tested cryoprotectants preserved the features of AFSCs however, variations in cell viability were observed. In this concern, dimethyl sulfoxide (Me2SO) showed the best results. The freezing protocols tested did not promote significant changes in the AFSCs viability. Time programmed and nonprogrammed freezing methods could be used for successful AFSCs cryopreservation for 6 months. Although tested cryoprotectants maintained undifferentiated gene expression, typical markers, and plasticity of AFSCs, only Me2SO and glycerol presented workable viability ratios.

1 May 2009 in Revista Brasileira de Ginecologia e Obstetrícia
Verified
Journal Article
Open access
PDF file
Sergio BydlowskiSergio Bydlowski
Sergio Bydlowski
ADAdriana A. Debes
Adriana A. Debes
LMLuciana M. F. Maselli
Luciana M. F. Maselli
FJFelipe de Lara Janz
Felipe de Lara Janz
Células-tronco são células indiferenciadas. Como tal, apresentam uma série de características que as tornam candidatas à utilização terapêutica. As principais características das células-tronco são a capacidade de autorrenovação e de se diferenciarem em diversos tipos celulares. Desta forma, acredita-se que células-tronco presentes nos diferentes tecidos tenham papel regenerativo quando estes sofrem uma lesão ou injúria. Entre os tecidos conhecidos por apresentarem células-tronco após a vida pós-natal, a medula óssea foi a mais estudada, por muitos anos, como fonte tanto de células-tronco hematopoéticas quanto de células-tronco mesenquimais, também denominadas de células mesenquimais estromais da medula óssea ou células estromais mesenquimais multipotentes. Estas células são um grupo de células clonogênicas, presentes no estroma da medula óssea, que, quando submetidas a diferentes estímulos apropriados, são capazes de se diferenciarem em várias linhagens de células, como a osteogênica, a condrogênica e a adipogênica e, possivelmente, em outros tipos celulares não mesodérmicos, como células neurais ou hepatócitos. Nesta revisão, as principais características das células-tronco mesenquimais serão abordadas, incluindo os marcadores moleculares e de membrana, as características de divisão e de diferenciação, a heterogeneidade e as aplicações clínicas potenciais.Stem cells are undifferentiated cells. They show various characteristics that make them suitable for clinical applications. The main stem cell characteristics are their capacity of autorenewal and of differentiation into different cell lines so it is quite possible that stem cells in different tissues exhibit a regenerative role when these tissues are injured. Bone marrow is the best studied tissue as a source of hematopoietic stem cells as well as mesenchymal stem cells (also known as mesenchymal stromal cells or mesenchymal stromal multipotent cells); clonogenic cells in the bone marrow stroma. They are able to differentiate under specific stimuli in several cell lines including osteogenic, chondrogenic and adipogenic cells, and probably in other nonmesodermic cell lines such as neural cells or hepatocytes. Here the main characteristics of mesenchymal stem cells will be discussed, including the molecular and membrane markers, the division and differentiation properties, the heterogeneity, and the potential clinical applications

1 September 2011 in Kidney International Supplements
Verified
Journal Article
Closed access
INIRENE NORONHA
IRENE NORONHA
RCRita C. Cavaglieri
Rita C. Cavaglieri
FJFelipe de Lara Janz
Felipe de Lara Janz
SDSergio A. Duarte
Sergio A. Duarte
MLMarco A.B. Lopes
Marco A.B. Lopes
Sergio BydlowskiSergio Bydlowski
Sergio Bydlowski

1 January 2012 in Revista Brasileira de Ginecologia e Obstetrícia
Verified
Journal Article
Open access
ESElíseo Joji Sekiya
Elíseo Joji Sekiya
AFAndresa Forte
Andresa Forte
TKTelma Ingrid Borges de Bellis Kühn
Telma Ingrid Borges de Bellis Kühn
FJFelipe de Lara Janz
Felipe de Lara Janz
Sergio BydlowskiSergio Bydlowski
Sergio Bydlowski
AAAdelson Alves
Adelson Alves
Adult stem/progenitor cells are found in different human tissues. An in vitro cell culture is needed for their isolation or for their expansion when they are not available in a sufficient quantity to regenerate damaged organs and tissues. The level of complexity of these new technologies requires adequate facilities, qualified personnel with experience in cell culture techniques, assessment of quality and clear protocols for cell production. The rules for the implementation of cell therapy centers involve national and international standards of good manufacturing practices. However, such standards are not uniform, reflecting the diversity of technical and scientific development. Here standards from the United States, the European Union and Brazil are analyzed. Moreover, practical solutions encountered for the implementation of a cell therapy center appropriate for the preparation and supply of cultured cells for clinical studies are described. Development stages involved the planning and preparation of the project, the construction of the facility, standardization of laboratory procedures and development of systems to prevent cross contamination. Combining the theoretical knowledge of research centers involved in the study of cells with the practical experience of blood therapy services that manage structures for cell transplantation is presented as the best potential for synergy to meet the demands to implement cell therapy centers.

24 October 2012 in Fundamental & Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
FJFelipe de Lara Janz
Felipe de Lara Janz
GFGiovani Marino Favero
Giovani Marino Favero
MBMilton Sérgio Bohatch
Milton Sérgio Bohatch
ADAdrianade Aguiar Debes
Adrianade Aguiar Debes
Sergio BydlowskiSergio Bydlowski
Sergio Bydlowski

2 January 2015 in Biomedical Science and Engineering
Verified
Journal Article
Closed access
PDF file
FJFelipe de Lara Janz
Felipe de Lara Janz
HLHelen Dutra Leite
Helen Dutra Leite
SBSergio Paulo Bydlowski
Sergio Paulo Bydlowski
Mesenchymal stem cells (MSCs) are described as undifferentiated cells with high capacity for self-renewal and differentiation ability in different tissues. MSCs are found in various locations in the adult organism as bone marrow, adipose tissue; and in fetal tissues as umbilical cord, placenta and amniotic fluid. They are able to produce and secrete a number of bioactive molecules with different effects: anti-fibrotic, angiogenic and mitogen. These cells also present a great immunomodulatory and anti-inflammatory potential described in experimental and human models. Several studies have demonstrated the ability of MSCs to suppress the proliferation and activation of T, B and NK cells in vitro and in vivo. Its low immunogenic action causes are not recognized by HLA mismatched receptor complex because they express low levels of MHC-I do not express MHC-II and costimulatory molecules CD40, CD80 and CD86. Because of these unique characteristics, MSCs arouse great interest in possible clinical applications in the therapy of diseases that affect the immune system. Although depending on the tissue microenvironment, the MSCs can also trigger inflammatory events. In this work, we described the main factors and another structures involved in MSCs immunoregulation.